Semax

World Peptide Foundation

Where is Semax being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Semax →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Synthetic regulatory peptide

Synthetic ACTH-fragment-derived heptapeptide studied chiefly in Russian-language neurobiology and clinical literature.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/20/2026
Documented human review:: No documented human review recorded
Automated scientific assessment:: None recorded
AI source check:: 9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

291

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

291

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

Independent evidence dossiers covering the major research questions.

Published source records

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

5 published domain syntheses connected to 0 featured studies

Semax no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas

Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓

2018Phase 1–2 human evidence

[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

PubMed-indexed clinical trial; journal article examining [the efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: E I Gusev; M Yu Martynov; E V Kostenko; L V Petrova; S N Bobyreva
Source: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
DOI: 10.17116/jnevro20181183261-68
PubMed: 29798983

Open original source

2026Observational human evidence

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

PubMed-indexed journal article; review examining therapeutic peptides in orthopaedics: applications, challenges, and future directions. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Omar F Rahman; Steven J Lee; William A Seeds
Source: Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
DOI: 10.4155/fdd-2022-0009
PubMed: 41490200

Open original source

2018Observational human evidence

Pharmacological Aspects of Neuro-Immune Interactions.

PubMed-indexed journal article; research support, non-u.s. gov't; review examining pharmacological aspects of neuro-immune interactions. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Vadim V Tarasov; Nikita V Kudryashov; Vladimir N Chubarev; Tatiana S Kalinina; George E Barreto; Ghulam Md Ashraf; Gjumrakch Aliev
Source: Current pharmaceutical design
DOI: 10.2174/1381612823666170829135115
PubMed: 28875850

Open original source

2021Observational human evidence

The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

PubMed-indexed journal article; research support, non-u.s. gov't examining the influence of selank on the level of cytokines under the conditions of "social" stress. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Yasenyavskaya A Leonidovna; Samotrueva M Aleksandrovna; Tsibizova A Aleksandrovna; Bashkina O Aleksandrovna; Myasoedov N Fedorovich; Andreeva L Aleksandrovna
Source: Current reviews in clinical and experimental pharmacology
DOI: 10.2174/1574884715666200704152810
PubMed: 32621722

Open original source

2016Observational human evidence

[POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].

PubMed-indexed journal article; review examining [possible role of transthyretin in the biological mechanism of the regulatory peptide neuroprotection.]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: T V Vyunova; E V Medvedeva; L A Andreeva; L V Dergunova; S A Limborska; N F Myasoedov
Source: Molekuliarnaia genetika, mikrobiologiia i virusologiia
PubMed: 30383932

Open original source

2006Observational human evidence

[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].

PubMed-indexed comparative study; journal article; review examining [comparison of anticoagulant effects of regulatory proline-containing oligopeptides. specificity of glyprolines, semax, and selank and potential of their practical application]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: L A Liapina; V E Pastorova; T Iu Obergan; G E Samonina; I P Ashmarin; N F Miasoedov
Source: Izvestiia Akademii nauk. Seriia biologicheskaia
PubMed: 16634437

Open original source

2026Observational human evidence

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

PubMed-indexed journal article; review examining therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Volodymyr Mavrych; Inna Shypilova; Olena Bolgova
Source: Frontiers in aging
DOI: 10.1038/s41392-022-00904-4
PubMed: 42021992

Open original source

2017Observational human evidence

Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.

PubMed-indexed journal article examining influence of actg4-7-pgp (semax) on morphofunctional state of hepatocytes in chronic emotional and painful stress. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: A V Ivanov; I I Bobyntsev; O M Shepeleva; A A Kryukov; L A Andreeva; N F Myasoedov
Source: Bulletin of experimental biology and medicine
DOI: 10.1007/s10517-017-3748-4
PubMed: 28577097

Open original source

2020Observational human evidence

Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

PubMed-indexed journal article examining correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: A A Elagina; Yu D Lyashev; A Yu Lyashev; T V Pronyaeva; A R Chahine
Source: Bulletin of experimental biology and medicine
DOI: 10.1007/s10517-020-04764-2
PubMed: 32246363

Open original source

2017Observational human evidence

[A comparative chemoreactome analysis of mexidol].

PubMed-indexed journal article examining [a comparative chemoreactome analysis of mexidol]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: I Yu Torshin; O A Gromova; I S Sardaryan; L E Fedotova
Source: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
DOI: 10.17116/jnevro20171171275-84
PubMed: 28514338

Open original source

2014Observational human evidence

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.

PubMed-indexed journal article; review examining sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Scott L Charland; Eric J Stanek
Source: Pharmacotherapy
DOI: 10.1002/phar.1368
PubMed: 24877185

Open original source

2008Observational human evidence

[Evolution of the stress concept].

PubMed-indexed english abstract; journal article; review examining [evolution of the stress concept]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: K V Sudakov
Source: Vestnik Rossiiskoi akademii meditsinskikh nauk
PubMed: 19140465

Open original source

2010Observational human evidence

[Nootropic and analgesic effects of Semax following different routes of administration].

PubMed-indexed english abstract; journal article examining [nootropic and analgesic effects of semax following different routes of administration]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: D M Manchenko; N Iu Glazova; N G Levitskaia; L A Andreeva; A A Kamenskiĭ; N F Miasoedov
Source: Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova
PubMed: 21268834

Open original source

2020Observational human evidence

Functional Connectomic Approach to Studying Selank and Semax Effects.

PubMed-indexed journal article examining functional connectomic approach to studying selank and semax effects. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ya R Panikratova; I S Lebedeva; O Yu Sokolov; A D Rumshiskaya; D A Kupriyanov; N V Kost; N F Myasoedov
Source: Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
DOI: 10.1134/S001249662001007X
PubMed: 32342318

Open original source

2013Animal research

Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain.

PubMed-indexed journal article; research support, non-u.s. gov't examining effect of semax and its c-terminal fragment pro-gly-pro on the expression of vegf family genes and their receptors in experimental focal ischemia of the rat brain. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ekaterina V Medvedeva; Veronika G Dmitrieva; Oksana V Povarova; Svetlana A Limborska; Veronika I Skvortsova; Nikolay F Myasoedov; Lyudmila V Dergunova
Source: Journal of molecular neuroscience : MN
DOI: 10.1007/s12031-012-9853-y
PubMed: 22772900

Open original source

2021Animal research

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.

PubMed-indexed journal article examining brain protein expression profile confirms the protective effect of the acth(4-7)pgp peptide (semax) in a rat model of cerebral ischemia-reperfusion. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Olga Yu Sudarkina; Ivan B Filippenkov; Vasily V Stavchansky; Alina E Denisova; Vadim V Yuzhakov; Larisa E Sevan'kaeva; Liya V Valieva; Julia A Remizova; Veronika G Dmitrieva; Leonid V Gubsky; Nikolai F Myasoedov; Svetlana A Limborska
Source: International journal of molecular sciences
DOI: 10.32388/uq8dyz
PubMed: 34201112

Open original source

2021Animal research

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

PubMed-indexed journal article examining semax, synthetic acth(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Nataliya Yu Glazova; Daria M Manchenko; Maria A Volodina; Svetlana A Merchieva; Ludmila A Andreeva; Vladimir S Kudrin; Nikolai F Myasoedov; Natalia G Levitskaya
Source: Neuropeptides
DOI: 10.1016/j.npep.2020.102114
PubMed: 33418449

Open original source

2024Animal research

ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.

PubMed-indexed journal article examining acth-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ivan B Filippenkov; Yana Yu Shpetko; Vasily V Stavchansky; Alina E Denisova; Leonid V Gubsky; Lyudmila A Andreeva; Nikolay F Myasoedov; Svetlana A Limborska; Lyudmila V Dergunova
Source: Biomedicines
DOI: 10.1038/s41598-022-20623-8
PubMed: 39767736

Open original source

2017Animal research

Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.

PubMed-indexed journal article examining semax, an analog of acth(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ekaterina V Medvedeva; Veronika G Dmitrieva; Svetlana A Limborska; Nikolay F Myasoedov; Lyudmila V Dergunova
Source: Molecular genetics and genomics : MGG
DOI: 10.1007/s00438-017-1297-1
PubMed: 28255762

Open original source

2014Animal research

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.

PubMed-indexed journal article; research support, non-u.s. gov't examining the peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ekaterina V Medvedeva; Veronika G Dmitrieva; Oksana V Povarova; Svetlana A Limborska; Veronika I Skvortsova; Nikolay F Myasoedov; Lyudmila V Dergunova
Source: BMC genomics
DOI: 10.1161/01.STR.12.6.723
PubMed: 24661604

Open original source

2025Animal research

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.

PubMed-indexed journal article examining genes that associated with action of acth-like peptides with neuroprotective potential in rat brain regions with different degrees of ischemic damage. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ivan B Filippenkov; Yana Yu Shpetko; Daria A Ales; Vasily V Stavchansky; Alina E Denisova; Vadim V Yuzhakov; Natalia K Fomina; Leonid V Gubsky; Lyudmila A Andreeva; Nikolay F Myasoedov; Svetlana A Limborska; Lyudmila V Dergunova
Source: International journal of molecular sciences
DOI: 10.1101/gr.1239303
PubMed: 40650034

Open original source

2025Animal research

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

PubMed-indexed journal article examining the potential of the peptide drug semax and its derivative for correcting pathological impairments in the animal model of alzheimer's disease. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: A I Radchenko; E V Kuzubova; A A Apostol; V A Mitkevich; L A Andreeva; S A Limborska; Yu V Stepenko; V S Shmigerova; A V Solin; M V Korokin; M V Pokrovskii; N F Myasoedov
Source: Acta naturae
DOI: 10.32607/actanaturae.27808
PubMed: 41479572

Open original source

2025Animal research

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

PubMed-indexed journal article examining semax peptide targets the μ opioid receptor gene oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Rongjie Liu; Yituo Chen; Haosheng Huang; Xiang Li; Junlei Lv; Liting Jiang; Hongyi Jiang; Chenyu Wu; Weikai Chen; Hongwei Xu; Zhefan Zhu; Haoxu Cai
Source: British journal of pharmacology
DOI: 10.1111/bph.70122
PubMed: 40692165

Open original source

2020Animal research

Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

PubMed-indexed journal article; research support, non-u.s. gov't examining novel insights into the protective properties of acth(4-7)pgp (semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: Ivan B Filippenkov; Vasily V Stavchansky; Alina E Denisova; Vadim V Yuzhakov; Larisa E Sevan'kaeva; Olga Y Sudarkina; Veronika G Dmitrieva; Leonid V Gubsky; Nikolai F Myasoedov; Svetlana A Limborska; Lyudmila V Dergunova
Source: Genes
DOI: 10.1126/scitranslmed.aaf8732
PubMed: 32580520

Open original source

2021Animal research

[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain].

PubMed-indexed journal article examining [the peptide drug acth(4-7)pgp (semax) suppresses mrna transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain]. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors: L V Dergunova; V G Dmitrieva; I B Filippenkov; V V Stavchansky; A E Denisova; V V Yuzhakov; L E Sevan'kaeva; L V Valieva; O Y Sudarkina; L V Gubsky; N F Myasoedov; S A Limborska
Source: Molekuliarnaia biologiia
DOI: 10.31857/S0026898421010043
PubMed: 34097675

Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

Molecular formula: C37H51N9O10S
Molecular weight (Da): 813.9
Amino acid sequence: MEHFPGP
InChIKey: AFEHBIGDWIGTEH-AQRCPPRCSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2006 · study · Temporal status not established
[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].
Izvestiia Akademii nauk. Seriia biologicheskaia
2008 · study · Temporal status not established
[Evolution of the stress concept].
Vestnik Rossiiskoi akademii meditsinskikh nauk
2010 · study · Temporal status not established
[Nootropic and analgesic effects of Semax following different routes of administration].
Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova
2013 · study · Temporal status not established
Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain.
Journal of molecular neuroscience : MN
2014 · study · Temporal status not established
Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.
Pharmacotherapy
2014 · study · Temporal status not established
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.
BMC genomics
2016 · study · Temporal status not established
[POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].
Molekuliarnaia genetika, mikrobiologiia i virusologiia
2017 · study · Temporal status not established
Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.
Bulletin of experimental biology and medicine
2017 · study · Temporal status not established
[A comparative chemoreactome analysis of mexidol].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2017 · study · Temporal status not established
Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.
Molecular genetics and genomics : MGG
2018 · study · Temporal status not established
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2018 · study · Temporal status not established
Pharmacological Aspects of Neuro-Immune Interactions.
Current pharmaceutical design
2020 · study · Temporal status not established
Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.
Bulletin of experimental biology and medicine
2020 · study · Temporal status not established
Functional Connectomic Approach to Studying Selank and Semax Effects.
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
2020 · study · Temporal status not established
Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.
Genes
2021 · study · Temporal status not established
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.
Current reviews in clinical and experimental pharmacology
2021 · study · Temporal status not established
Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.
International journal of molecular sciences
2021 · study · Temporal status not established
Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.
Neuropeptides
2021 · study · Temporal status not established
[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain].
Molekuliarnaia biologiia
2024 · study · Temporal status not established
ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Biomedicines
2025 · study · Temporal status not established
Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.
International journal of molecular sciences
2025 · study · Temporal status not established
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
Acta naturae
2025 · study · Temporal status not established
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology
2026 · study · Temporal status not established
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
2026 · study · Temporal status not established
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Frontiers in aging
2026 · regulatory · Temporal status not established
Regulatory review: not_approved
European Union
2026 · regulatory · Temporal status not established
Regulatory review: not_approved
United States

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Svetlana A Limborska

7 represented evidence records

Years represented: 2013, 2014, 2017, 2020, 2021, 2024, 2025

Publishing organizations appearing in records: BMC genomics, Biomedicines, Genes, International journal of molecular sciences, Journal of molecular neuroscience : MN, Molecular genetics and genomics : MGG

3 represented evidence records

Years represented: 2013, 2014, 2017

Publishing organizations appearing in records: BMC genomics, Journal of molecular neuroscience : MN, Molecular genetics and genomics : MGG

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 5 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Semax evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

EMA medicines portal

United States

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

FDA compounding safety-risk list

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.

Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.

Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.

Contradictory and qualifying evidence must remain visible rather than being silently discarded.

Absence of represented evidence is not evidence that research does not exist.

Research gaps identify unresolved questions; they are not negative conclusions.

Regulatory status is distinct from scientific evidence quality.

Media relationships provide context and explanation; they do not increase the strength of scientific evidence.

A section with no represented records is an incomplete project record, not a scientific conclusion.

Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:44 PM

global evidence atlas

Semax research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

291Discoverable source universe

291Ranked screening records

5Research domains

0Accountably approved conclusions

SearchDomainEvidence class

Semax: what this atlas does and does not establish

Last checked: 2026-09-18
Accountable publication approval: Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

European Unionnot approvedchecked 2026-09-09
EMA medicines portal
United Statesnot approvedchecked 2026-09-09
FDA compounding safety-risk list

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Semax evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

APA
World Peptide Foundation. (n.d.). Semax — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/semax
AMA / Vancouver
World Peptide Foundation. Semax — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/semax

Where is Semax being studied?

Semax

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

5 published domain syntheses connected to 0 featured studies

[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Pharmacological Aspects of Neuro-Immune Interactions.

The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

[POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].

[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.

Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

[A comparative chemoreactome analysis of mexidol].

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.

[Evolution of the stress concept].

[Nootropic and analgesic effects of Semax following different routes of administration].

Functional Connectomic Approach to Studying Selank and Semax Effects.

Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain.

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.

Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain].

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].

[Evolution of the stress concept].

[Nootropic and analgesic effects of Semax following different routes of administration].

Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain.

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.

[POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].

Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.

[A comparative chemoreactome analysis of mexidol].

Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.

[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

Pharmacological Aspects of Neuro-Immune Interactions.

Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.

Functional Connectomic Approach to Studying Selank and Semax Effects.

Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain].

ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Regulatory review: not_approved

Regulatory review: not_approved

What still needs investigation

Claim traceability

Svetlana A Limborska

Lyudmila V Dergunova

N F Myasoedov

Nikolay F Myasoedov

Veronika G Dmitrieva

A E Denisova

Alina E Denisova

Ivan B Filippenkov

L A Andreeva

Leonid V Gubsky

Vasily V Stavchansky

Ekaterina V Medvedeva

Follow the scientific relationships

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova